NICE has announced that it has recommended two treatments (infliximab and adalimumab) for people with severe Crohn’s disease.
The guidance approves use of the drugs for people who have not responded to, who are intolerant of, or are unable to take more commonly used therapies to treat the condition. The guidance from NICE recommends infliximab and adalimumab as treatment options for adults with a severe, active form of the disease. Treatment should normally be started with the less expensive drug (taking into account drug administration costs, required dose and product price per dose).
